Advertisement

Topics

Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Corners...

20:00 EDT 16 Apr 2019 | BioSpace

Janssen Pharmaceuticals presented data that showed its RNA interference (RNAi) therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.

Original Article: Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Corners...

NEXT ARTICLE

More From BioPortfolio on "Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Corners..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...